Pathological response after neoadjuvant bevacizumab- or cetuximab-based chemotherapy in resected colorectal cancer liver metastases

Medical Oncology

Volumn 32, Issue 7, 2015, Pages 1-10

  Pietrantonio, Filippo ^a   Mazzaferro, Vincenzo ^a   Miceli, Rosalba ^a   Cotsoglou, Christian ^a   Melotti, Flavia ^b   Fanetti, Giuseppe ^a   Perrone, Federica ^a   Biondani, Pamela ^a   Muscarà, Cecilia ^a   Di Bartolomeo, Maria ^a   Coppa, Jorgelina ^a   Maggi, Claudia ^a   Milione, Massimo ^a   Tamborini, Elena ^a   de Braud, Filippo ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b Azienda Ospedaliera di Desenzano del Garda   (Italy)

Author keywords

Bevacizumab; Cetuximab; Colorectal cancer; Liver metastases; Neoadjuvant chemotherapy; Pathological response

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROPYRIMIDINE; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; KRAS PROTEIN, HUMAN; PROTEIN P21;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; CANCER SURGERY; COLORECTAL LIVER METASTASIS; FEMALE; GENE MUTATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; TREATMENT OUTCOME; TREATMENT RESPONSE; COLORECTAL NEOPLASMS; DISEASE FREE SURVIVAL; DRUG EFFECTS; GENETICS; LIVER; LIVER NEOPLASMS; LIVER RESECTION; MIDDLE AGED; MUTATION; PATHOLOGY; PROCEDURES; SECONDARY;

AGED; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BEVACIZUMAB; CETUXIMAB; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HEPATECTOMY; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PROTO-ONCOGENE PROTEINS P21(RAS); TREATMENT OUTCOME;

EID: 84952900828     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-015-0638-3     Document Type: Article

References (39)

1. Nordlinger B, van Cutsem E, Gruenberger T, et al. Combination of surgery and chemotherapy and the role of targeted agents in the treatment of patients with colorectal liver metastases: recommendations from an expert panel. Ann Oncol. 2009;20:985–92.
2. Adam R, Delvart V, Pascal G, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long term survival. Ann Surg. 2004;240:644–57.
3. Lam VW, Spiro C, Laurence JM, et al. A systematic review of clinical response and survival outcomes of downsizing systemic chemotherapy and rescue liver surgery in patients with initially unresectable colorectal liver metastases. Ann Surg Oncol. 2012;19:1292–301.
4. Nordlinger B, Sorbye H, Grimelius B, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet. 2008;371:1007–16.
5. Folprecht G, Grothey A, Alberts S, Raab HR, Köhne CH. Neoadjuvant treatment of unresectable colorectal liver metastases: correlation between tumour response and resection rates. Ann Oncol. 2005;16:1311–9.
6. Van Cutsem E, Kohne CH, Lang I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011–9.
7. Van Cutsem E, Köhne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med. 2009;360:1408–17.
8. Petrelli F, Barni S. Resectability and outcome with anti-EGFR agents in patients with KRAS wildtype colorectal liver-limited metastases. A metaanalysis. Int J Colorectal Dis. 2012;27:997–1004.
9. Folprecht G, Gruenberger T, Bechstein WO, et al. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial. Lancet Oncol. 2010;11:38–47.
10. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol. 2013;. doi:10.1200/JCO.2012.44.8308.
11. de Jong MC, Pulitano C, Ribero D, et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis: an international multi-institutional analysis of 1669 patients. Ann Surg. 2009;250(3):440–8.
12. Rees M, Tekkis PP, Welsh FK, et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. Ann Surg. 2008;247:125–35.
13. Zakaria S, Donohue JH, Que FG, et al. Hepatic resection for colorectal metastases: Value for risk scoring systems? Ann Surg. 2007;246:183–91.
14. Nordlinger B, Guiguet M, Vaillant JC, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Association Francaise de Chirurgie. Cancer. 1996;77:1254–62.
15. Blazer DG III, Kishi Y, Maru DM, et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol. 2008;25:5344–51.
16. Rubbia-Brandt L, Giostra E, Brezault C, et al. Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol. 2007;18:299–304.
17. Adam R, Wicherts DA, de Haas RJ, et al. Complete pathologic response after preoperative chemotherapy for colorectal liver metastases: Myth or reality? J Clin Oncol. 2008;26:1635–41.
18. Klinger M, Dietmar Tamandl D, Eipeldauer S, et al. Bevacizumab improves pathological response of colorectal cancer liver metastases treated with XELOX/FOLFOX. Ann Surg Oncol. 2010;17:2059–65.
19. Ribero D, Wang H, Donadon M, et al. Bevacizumab improves pathologic response and protects against hepatic injury in patients treated with oxaliplatin-based chemotherapy for colorectal liver metastases. Cancer. 2007;12:2761–7.
20. Perrone F, Lampis A, Orsenigo M, et al. PI3KCA/PTEN deregulation contributes to impaired responses to cetuximab in metastatic colorectal cancer patients. Ann Oncol. 2009;20:84–90.
21. Molinari F, Felicioni L, Buscarino M, et al. Increased detection sensitivity for KRAS mutations enhances the prediction of anti-EGFR monoclonal antibody resistance in metastatic colorectal cancer. Clin Cancer Res. 2011;17:4901–14.
22. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.
23. Zeger SL, Liang KY. Longitudinal data analysis using generalized linear models. Biometrica. 1986;73:13–22.
24. Firth D. Bias reduction of maximum likelihood estimates. Biometrika. 1993;80:27–38.
25. Goeman JJ. L-1 penalized estimation in the cox proportional hazards model. Biom J. 2010;52(1):70–84.
26. Durrleman S, Simon R. Flexible regression models with cubic splines. Stat Med. 1989;8:551–61.
27. Chun YS, Vauthey J-N, Boonsirikamchai P, et al. Association of computed tomography morphologic criteria with pathologic response and survival in patients treated with bevacizumab for colorectal liver metastases. JAMA. 2009;302:2338–44.
28. Shindoh J, Loyer EM, Kopetz S, et al. Optimal morphologic response to preoperative chemotherapy: an alternate outcome end point before resection of hepatic colorectal metastases. J Clin Oncol. 2012;30:4566–72.
29. Maru DM, Kopetz S, Boonsirikamchai P, et al. Tumor thickness at the tumor-normal interface: a novel pathologic indicator of chemotherapy response in hepatic colorectal metastases. Am J Surg Pathol. 2010;34:1287–94.
30. Kishi Y, Zorzi D, Contreras CM, et al. Extended preoperative chemotherapy does not improve pathologic response and increases postoperative liver insufficiency after hepatic resection for colorectal liver metastases. Ann Surg Oncol. 2010;17:2870–6.
31. Gruenberger T, Arnold D, Rubbia-Brandt L. Pathologic response to bevacizumab-containing chemotherapy in patients with colorectal liver metastases and its correlation with survival. Surg Oncol. 2012;21:309–15.
32. Karapetis C-S, Khambata-Ford S, Jonker DJ, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.
33. Zlobec I, Bihl MP, Schwarb H, et al. Clinicopathological and protein characterization of BRAF- and K-RAS-mutated colorectal cancer and implications for prognosis. Int J Cancer. 2010;127:367–80.
34. Andreyev HJ, Norman AR, Cunningham D, et al. Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study. Br J Cancer. 2001;85:692–6.
35. Stremitzer S, Stift J, Gruenberger B, et al. KRAS status and outcome of liver resection after neoadjuvant chemotherapy including bevacizumab. Br J Surg. 2012;99:1575–82.
36. Nash GM, Gimbel M, Shia J, et al. KRAS mutation correlates with accelerated metastatic progression in patients with colorectal liver metastases. Ann Surg Oncol. 2010;17:572–8.
37. Tie J, Lipton L, Desai J, et al. KRAS mutation is associated with lung metastasis in patients with curatively resected colorectal cancer. Clin Cancer Res. 2011;17:1122–30.
38. Carey LA, Dees EC, Sawyer L, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res. 2007;13:2329–34.
39. Pietrantonio F, Orlandi A, Inno A, et al. Bevacizumab-based neoadjuvant chemotherapy for colorectal cancer liver metastases: pitfalls and helpful tricks in a review for clinicians. Crit Rev Oncol Hematol. 2015. doi:10.1016/j.critrevonc.2015.04.008.